Printer Friendly

China Biologic passes GMP certification for new coagulation factor facility in China.

M2 EQUITYBITES-December 24, 2014-China Biologic passes GMP certification for new coagulation factor facility in China

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) reported on Tuesday the receipt of the Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.

This certification was awarded to the company's majority-owned subsidiary, Shandong Taibang Biological Products Co. The company said the CFDA inspected this new facility for GMP compliance in June 2014.

With immediate effect, the company's new certified facility will primarily produce plasma-derived prothrombin complex concentrate, factor VIII and various other coagulation factors are in the pipeline. This new facility has the capability to produce multiple coagulation factors concurrently and on a larger scale compared with its existing production facilities.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:9CHIN
Date:Dec 24, 2014
Words:147
Previous Article:Cal-Maine Foods reports increased net income of USD36.6m in Q2 fiscal 2015.
Next Article:Safeway announces completion of assets sale of its PDC subsidiary to Terramar Retail Centers for USD830m.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters